Skip to main content
Target Proteinuria logo
  • Proteinuria in glomerular disease
  • IgAN explained
    • Mechanism of disease
    • Epidemiology
    • Disease progression
    • Risk prediction
    • Current treatment
    • Watch Video
  • The dual pathway
  • Search search-icon

Help us guide you to the right place

This website is educational, non-promotional and intended for healthcare professionals in Europe, Australia and New Zealand. It is not intended for healthcare professionals within the United Kingdom or United States.

I am a healthcare professional residing in the United States

VISIT THE US SITE

I am a healthcare professional residing in the United Kingdom

VISIT VIFORPHARMA.COM/UK

I am a health care professional

THIS IS ME, CONTINUE

I am not a health care professional

THIS IS ME, CONTINUE

IgAN  
EXPLAINED

  2. IgAN explained
  3. Mechanism of disease

Abbreviations

GFR, glomerular filtration rate; IgA, Immunoglobulin A; IgA1, Immunoglobulin A-1; IgAN, IgA nephropathy

References

1. Wyatt R, Julian B. IgA Nephropathy. N Engl J Med. 2013; 368:2402–14. 2. Barratt J, Feehally J. IgA Nephropathy. J Am Soc Nephrol. 2005; 16:2088–97. 3. Boyd JK, et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012; 81:833–43. 4. Aucella F, et al. Proteinuria in the prognosis of IgA nephropathy. Minerva Urol Nefrol. 2009; 61:235–48. 5. Remuzzi G, Bertani T. Pathophysiology of Progressive Nephropathies. N Engl J Med. 1998; 339:1448–56. 6. Suzuki H, et al. The Pathophysiology of IgA Nephropathy.  J Am Soc Nephrol. 2011; 22:1975–1803. 7. Lai KN, et al. IgA nephropathy. Nat Rev Dis Primers. 2016; 2:16001.

 

Healthcare professionals may request a full copy of the cited clinical trial report from Vifor Pharma Switzerland AG.

Address

Vifor Pharma Management Ltd
Flughofstrasse
61 P.O. Box 8152
Glattbrugg
Switzerland

Stay in touch

Keep up to date on social media or contact us for any other information

T: +41 (0) 58 851 8000

F: +41 (0) 58 851 8001

E: medinfo@viforpharma.com

This website is educational, non-promotional and intended for healthcare professionals in Europe, Australia and New Zealand. It is not intended for healthcare professionals within the United Kingdom or United States.

CSL Logo

This website is educational, non-promotional and intended for healthcare professionals in Europe, Australia and New Zealand. It is not intended for healthcare professionals within the United Kingdom or United States. For more information contact medinfo@viforpharma.com.

Copyright © 2023

  • Terms of use
  • Privacy policy
  • Cookie policy
  • CH-SPT-2400010
  • E 05/2024